Search

Your search keyword '"Ohr, James"' showing total 14 results
Start Over Author "Ohr, James" Publisher wiley
14 results on '"Ohr, James"'

1. A phase Ⅱ prospective trial of photobiomodulation therapy in limiting oral mucositis in the treatment of locally advanced head and neck cancer patients

Author

Taylor, Janielle K.‐A., primary, Mady, Leila J., additional, Baddour, Khalil, additional, Iheagwara, Uzoma K., additional, Zhai, Shuyan, additional, Ohr, James P., additional, Zandberg, Daniel P., additional, Gorantla, Vikram C., additional, Ferris, Robert L., additional, Kim, Seungwon, additional, Duvvuri, Umamaheswar, additional, Kubik, Mark W., additional, Sridharan, Shaum, additional, Johnson, Jonas T., additional, Holeva, Karen D., additional, Quinn, Annette E., additional, and Clump, David A., additional

Published
2022
Full Text
View/download PDF

2. Definitive local therapy to head and neck squamous cell carcinoma with distant metastasis

Author

Borson, Steven, primary, Shuai, Yongli, additional, Branstetter, Barton F., additional, Nilsen, Marci Lee, additional, Hughes, Marion A., additional, Fenton, Moon, additional, Kubik, Mark, additional, Sridharan, Shaum, additional, Clump, David A., additional, Skinner, Heath D., additional, Johnson, Jonas T., additional, Chiosea, Simion I., additional, Ohr, James, additional, Duvvuri, Umamaheswar, additional, Kim, Seungwon, additional, Traylor, Katie S., additional, Ferris, Robert, additional, and Zandberg, Dan P., additional

Published
2022
Full Text
View/download PDF

3. Transition to a virtual multidisciplinary tumor board during the COVID ‐19 pandemic: University of Pittsburgh experience

Author

Dharmarajan, Harish, primary, Anderson, Jennifer L., additional, Kim, Seungwon, additional, Sridharan, Shaum, additional, Duvvuri, Umamaheswar, additional, Ferris, Robert L., additional, Solari, Mario G., additional, Clump, David A., additional, Skinner, Heath D., additional, Ohr, James P., additional, Zandberg, Dan P., additional, Branstetter, Barton, additional, Hughes, Marion A., additional, Traylor, Katie S., additional, Seethala, Raja, additional, Chiosea, Simion I., additional, Nilsen, Marci L., additional, Johnson, Jonas T., additional, and Kubik, Mark W., additional

Published
2020
Full Text
View/download PDF

5. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma

Author

Brand, Randall, primary, Borazanci, Erkut, additional, Speare, Virginia, additional, Dudley, Beth, additional, Karloski, Eve, additional, Peters, Mary Linton B., additional, Stobie, Lindsey, additional, Bahary, Nathan, additional, Zeh, Herbert, additional, Zureikat, Amer, additional, Hogg, Melissa, additional, Lee, Kenneth, additional, Tsung, Allan, additional, Rhee, John, additional, Ohr, James, additional, Sun, Weijing, additional, Lee, James, additional, Moser, A. James, additional, DeLeonardis, Kim, additional, Krejdovsky, Jill, additional, Dalton, Emily, additional, LaDuca, Holly, additional, Dolinsky, Jill, additional, Colvin, Arlene, additional, Lim, Cynthia, additional, Black, Mary Helen, additional, and Tung, Nadine, additional

Published
2018
Full Text
View/download PDF

13. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.

Author

Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee JJ, Bahary N, Chu E, Streeter N, and Drummond S

Subjects
Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors adverse effects, Antineoplastic Agents adverse effects, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Phenylurea Compounds adverse effects, Pyridines adverse effects, Survival Analysis, Treatment Outcome, Adenocarcinoma drug therapy, Angiogenesis Inhibitors administration & dosage, Antineoplastic Agents administration & dosage, Biliary Tract Neoplasms drug therapy, Phenylurea Compounds administration & dosage, Pyridines administration & dosage
Abstract

Background: Biliary tract cancers are rare, aggressive neoplasms. Most patients present with advanced/unresectable or metastatic disease at diagnosis, and no second-line regimen has demonstrated clinical benefit. This was a phase 2 study evaluating the efficacy and safety of regorafenib in patients who had advanced/unresectable or metastatic disease after receiving standard therapy., Methods: In this single arm-study, patients with advanced/unresectable or metastatic biliary tract cancer who failed at least 1 line of systemic chemotherapy received regorafenib once daily on a schedule of 21-days on/7-days off in a 28-day cycle. Patients initially received a standard 160 mg dose. After toxicity assessments in the first 3 patients, the dose was reduced to 120 mg for subsequent patients, as preplanned. The primary endpoint was progression-free survival (PFS). Secondary objectives included overall survival (OS), the objective response rate, and the disease control rate., Results: Forty-three patients received at least 1 dose of regorafenib, and 34 patients who received at least 1 cycle of treatment were evaluable for tumor response. The median PFS was 15.6 weeks (90% confidence interval, 12.9-24.7 weeks), and the median OS was 31.8 weeks (90% confidence interval, 13.3-74.3 weeks), with survival rates 40% at 12 months and 32% at 18 months. A partial response was achieved in 5 patients (11%), and 19 had stable disease (44%), for a disease control rate of 56%. The toxicity profile was as expected, with grade 3 and 4 adverse events reported in 40% of patients. The most common toxicities were hypophosphatemia (40%), hyperbilirubinemia (26%), hypertension (23%), and hand-foot skin reaction (7%)., Conclusions: The current results suggest promising efficacy of regorafenib in patients with chemotherapy-refractory, advanced/metastatic biliary tract cancer, warranting further studies to confirm its clinical efficacy. There is a clear unmet need for effective therapies in patients who have advanced and metastatic biliary tract cancer., (© 2018 American Cancer Society.)

Published
2019
Full Text
View/download PDF

14. Oncologic and functional outcomes of partial laryngeal surgery for intermediate-stage laryngeal cancer.

Author

Caicedo-Granados E, Beswick DM, Christopoulos A, Cunningham DE, Razfar A, Ohr JP, Heron DE, and Ferris RL

Subjects
Adult, Aged, Aged, 80 and over, Biopsy, Carcinoma, Squamous Cell pathology, Confidence Intervals, Female, Humans, Laryngeal Neoplasms pathology, Laryngectomy, Male, Middle Aged, Neck Dissection, Neoplasm Staging, Proportional Hazards Models, Recovery of Function, Retrospective Studies, Statistics, Nonparametric, Survival Rate, Treatment Outcome, Carcinoma, Squamous Cell surgery, Laryngeal Neoplasms surgery
Abstract

Objective: To evaluate the oncologic and functional outcomes of partial laryngeal surgery (PLS) using transoral laser microsurgery (TLM) and supracricoid laryngectomy (SCL) in patients with intermediate-stage laryngeal squamous cell carcinoma (LSCC)., Study Design: Historical cohort study., Setting: Single tertiary care center., Subjects and Methods: Retrospective review of oncologic and functional outcomes in intermediate-stage (T2-3/N0-1, stage II and III) LSCC patients who underwent TLM or SCL from 1998 to 2010., Results: Sixty patients were included, of whom 28 (47%) underwent TLM and 32 (53%) underwent SCL. For the entire cohort, 2- and 5-year probabilities were 86.2% (95% confidence interval [CI], 73.0%-93.2%) and 72.9% (95% CI, 52.4%-85.6%), respectively, for overall survival (OS) and 79.3% (95% CI, 65.6%-88.0%) and 62.4% (95% CI, 41.9%-77.4%), respectively, for recurrence-free survival (RFS). There was no difference between the TLM and SCL cohorts in OS (P = .542) or RFS (P = .483). More than 75% of patients avoided adjuvant therapy. Communication Scale and Functional Outcome Swallowing Scale scores at median follow-up of 33 months were 2 or better in 97% and 91% of patients, respectively, reflecting functional voice and swallowing postoperatively. Eighty-eight percent of patients retained a functional larynx., Conclusion: PLS provides excellent oncologic and functional outcomes for intermediate-stage LSCC and should be considered an alternative to chemoradiation or total laryngectomy in selected patients.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results